RESUMEN
Despite being subject to lower AIDS-related mortality rates and having a higher life expectancy, patients with HIV are more prone to develop non-AIDS events. A low CD4+/CD8+ ratio during antiretroviral therapy identifies people with heightened immune senescence and increased risk of mortality. In clinical practice, finding determinants of a low CD4+/CD8+ ratio may be useful for identifying patients who require close monitoring due to an increased risk of comorbidities and death. We performed a prospective study on the evolution of the CD4+/CD8+ ratio in 60 patients infected with HIV (80% males), who were subjected to two different antiretroviral regimens: early and deferred therapy. The initial CD4+/CD8+ ratio was ≤1 for 70% of the patients in both groups. Older age, CD4+ cell count at inclusion, Nadir CD8+T-cell count, and Initial CD4+/CD8+ ratio ≤ 1 were risk factors for lack of ratio recovery. In the multivariate analysis, a CD4+/CD8+ ratio > 1 at the start of the treatment was found to be a determinant factor in maintaining a CD4+/CD8+ ratio > 1. The nadir CD4+T-cell count was lower in the deferred therapy group (p=0.004), and the last CD4+/CD8+ ratio ≤1 was not associated with comorbidities. Ratio recovery was not associated with the duration of HIV infection, time without therapy, or absence of AIDS incidence. A greater improvement was observed in patients treated early (p=0.003). In contrast, the slope of increase was slower in patients who deferred treatment. In conclusion, the increase in the CD4+/CD8+ ratio occurred mostly for patients undergoing early strategy treatment and its extension did not seem to be related to previous HIV-related factors.
Asunto(s)
Síndrome de Inmunodeficiencia Adquirida , Fármacos Anti-VIH , Infecciones por VIH , Masculino , Humanos , Femenino , Infecciones por VIH/complicaciones , Estudios Prospectivos , Terapia Antirretroviral Altamente Activa , Linfocitos T CD8-positivos , Recuento de Linfocito CD4 , Linfocitos T CD4-Positivos , Fármacos Anti-VIH/uso terapéutico , Carga ViralRESUMEN
Persistent viruses are hard to be eradicated, even using effective medications, and can persist for a long time in humans, sometimes regardless of treatment. Hepatitis B virus, hepatitis C virus, human immunodeficiency virus, and human T cell lymphotropic virus infections, the most common in our era, are still a challenge despite the increased knowledge about their biology. Most of them are highly pathogenic, some causing acute disease or, more often, leading to chronic persistent infections, and some of the occult, carrying a high risk of morbidity and mortality. However, if such infections were discovered early, they might be eradicated in the near future with effective medications and/or vaccines. This perspective review points out some specific characteristics of the most important chronic persistent viruses. It seems that in the next few years, these persistent viruses may have control by vaccination, epidemiological strategies, and/or treatment.
Asunto(s)
Infecciones por VIH , Infecciones por HTLV-I , Hepatitis B , Hepatitis C , Virus Linfotrópico T Tipo 1 Humano , Humanos , VIH , Virus de la Hepatitis B , Hepacivirus , Hepatitis B/epidemiología , Hepatitis B/prevención & control , Infección Persistente , Infecciones por VIH/complicaciones , Infecciones por VIH/epidemiologíaRESUMEN
ABSTRACT Despite being subject to lower AIDS-related mortality rates and having a higher life expectancy, patients with HIV are more prone to develop non-AIDS events. A low CD4+/CD8+ ratio during antiretroviral therapy identifies people with heightened immune senescence and increased risk of mortality. In clinical practice, finding determinants of a low CD4+/CD8+ ratio may be useful for identifying patients who require close monitoring due to an increased risk of comorbidities and death. We performed a prospective study on the evolution of the CD4+/CD8+ ratio in 60 patients infected with HIV (80% males), who were subjected to two different antiretroviral regimens: early and deferred therapy. The initial CD4+/CD8+ ratio was ≤1 for 70% of the patients in both groups. Older age, CD4+ cell count at inclusion, Nadir CD8+T-cell count, and Initial CD4+/CD8+ ratio ≤ 1 were risk factors for lack of ratio recovery. In the multivariate analysis, a CD4+/CD8+ ratio > 1 at the start of the treatment was found to be a determinant factor in maintaining a CD4+/CD8+ ratio > 1. The nadir CD4+T-cell count was lower in the deferred therapy group (p=0.004), and the last CD4+/CD8+ ratio ≤1 was not associated with comorbidities. Ratio recovery was not associated with the duration of HIV infection, time without therapy, or absence of AIDS incidence. A greater improvement was observed in patients treated early (p=0.003). In contrast, the slope of increase was slower in patients who deferred treatment. In conclusion, the increase in the CD4+/CD8+ ratio occurred mostly for patients undergoing early strategy treatment and its extension did not seem to be related to previous HIV-related factors.
RESUMEN
BACKGROUND: Mother-to-child transmission (MTCT) of human T-lymphotropic virus type 1 (HTLV-1) is an important route of transmission that can cause lifelong infection. There is high morbidity and mortality due to adult T-cell leukemia/lymphoma, HTLV-1-associated myelopathy (HAM), and other inflammatory disorders. These conditions develop in nearly 10% of people with HTLV-1 infection, with a higher risk if infection occurs early in life. Identification of risk factors can inform targeted measures to reduce HTLV-1 MTCT. This study aimed to investigate the potential of cesarean delivery to prevent HTLV-1 MTCT. METHODS: We performed a review of the cases of women and their offspring under regular follow-up at the HTLV-1 outpatient clinic at the Institute of Infectious Diseases Emilio Ribas. RESULTS: A total of 177 HTLV-1-infected women and 369 adult offspring were investigated. Overall, 15% of the children were positive for HTLV-1 and 85% were negative. Regarding vertical transmission, we found that a breastfeeding duration of >6 months was associated with MTCT. Moreover, maternal proviral load was not associated with transmission, but high educational level and cesarean delivery were identified as protective factors. CONCLUSIONS: HTLV-1 MTCT was associated with mother's age at delivery of >25 years, low educational level, prolonged breastfeeding, and vaginal delivery.
Asunto(s)
Infecciones por HTLV-I , Virus Linfotrópico T Tipo 1 Humano , Paraparesia Espástica Tropical , Adulto , Embarazo , Humanos , Femenino , Transmisión Vertical de Enfermedad Infecciosa/prevención & control , Infecciones por HTLV-I/prevención & control , Lactancia MaternaRESUMEN
BACKGROUND: HTLV-1-Associated Myelopathy/Tropical Spastic Paraparesis (HAM/TSP) is an incapacitating neuroinflammatory disorder for which no disease-modifying therapy is available, but corticosteroids provide some clinical benefit. Although HAM/TSP pathogenesis is not fully elucidated, older age, female sex and higher proviral load are established risk factors. We investigated systemic cytokines and a novel chronic inflammatory marker, GlycA, as possible biomarkers of immunopathogenesis and therapeutic response in HAM/TSP, and examined their interaction with established risk factors. PATIENTS AND METHODS: We recruited 110 People living with HTLV-1 (PLHTLV-1, 67 asymptomatic individuals and 43 HAM/TSP patients) with a total of 946 person-years of clinical follow-up. Plasma cytokine levels (IL-2, IL-4, IL-6, IL-10, IL-17A, IFN-γ, TNF) and GlycA were quantified by Cytometric Bead Array and 1NMR, respectively. Cytokine signaling and prednisolone response were validated in an independent cohort by nCounter digital transcriptomics. We used multivariable regression, machine learning algorithms and Bayesian network learning for biomarker identification. RESULTS: We found that systemic IL-6 was positively correlated with both age (r = 0.50, p < 0.001) and GlycA (r = 0.45, p = 0.00049) in asymptomatics, revealing an 'inflammaging" signature which was absent in HAM/TSP. GlycA levels were higher in women (p = 0.0069), but cytokine levels did not differ between the sexes. IFN-γ (p = 0.007) and IL-17A (p = 0.0001) levels were increased in untreated HAM/TSP Multivariable logistic regression identified IL-17A and proviral load as independent determinants of clinical status, resulting in modest accuracy of predicting HAM/TSP status (64.1%), while a machine learning-derived decision tree classified HAM/TSP patients with 90.7% accuracy. Pre-treatment GlycA and TNF levels significantly predicted clinical worsening (measured by Osame Motor Disability Scale), independent of proviral load. In addition, a poor prednisolone response was significantly correlated with higher post-treatment IFN-γ levels. Likewise, a transcriptomic IFN signaling score, significantly correlated with previously proposed HAM/TSP biomarkers (CASP5/CXCL10/FCGR1A/STAT1), was efficiently blunted by in vitro prednisolone treatment of PBMC from PLHTLV-1 and incident HAM/TSP. CONCLUSIONS: An age-related increase in systemic IL-6/GlycA levels reveals inflammaging in PLHTLV-1, in the absence of neurological disease. IFN-γ and IL-17A are biomarkers of untreated HAM/TSP, while pre-treatment GlycA and TNF predict therapeutic response to prednisolone pulse therapy, paving the way for a precision medicine approach in HAM/TSP.
Asunto(s)
Infecciones por HTLV-I , Trastornos Motores , Enfermedades Neuroinflamatorias , Femenino , Humanos , Teorema de Bayes , Citocinas , Virus Linfotrópico T Tipo 1 Humano , Interleucina-17 , Interleucina-6 , Leucocitos Mononucleares , Trastornos Motores/virología , Enfermedades Neuroinflamatorias/virología , Infecciones por HTLV-I/complicacionesRESUMEN
Interferon-gamma (IFN-γ) plays a crucial role in viral infections by preventing viral replication and in the promotion of innate and adaptive immune responses. However, IFN-gamma can exert distinct effects in different persistent viral infections. The long-term overproduction of IFN-γ in retroviral infections, such as the human immunodeficiency virus (HIV), human T-lymphotropic virus type 1 (HTLV-1), and human endogenous retroviruses (HERVs), resulting in inflammation, may cause neuronal damage. This review is provocative about the role of IFN-γ during persistent retroviral infections and its relationship with the causation of some neurological disorders that are important for public health.
Asunto(s)
Infecciones por VIH , Virus Linfotrópico T Tipo 1 Humano , Citocinas , Humanos , Inflamación , Interferón gammaRESUMEN
INTRODUCTION: People living with Human Immunodeficiency Virus (HIV) are under risk for co-infection with SARS-CoV-2. This population may be more prone to complications from COVID-19 due to persistent inflammation caused by HIV and higher incidence of metabolic syndromes, cardiovascular diseases, and malignancies, as well as being considered elderly at 50 years of age. The objective of this study was to report SARS-CoV-2 infection frequency, clinical evolution, and mortality in HIV-positive patients on antiretroviral therapy. METHODS: The period of inquiry ranged from January to September 2020. Due to the social distance and the suspension of in-person medical care during the time of the investigation, we sent electronic questions about demographic, epidemiological, and clinical data to 403 HIV-infected patients. RESULTS: Among 260 patients who answered the questionnaire, thirty-nine patients (15%) had suggestive symptoms and were tested for SARS-CoV-2 infection. Of this, 11 had positive results (32.4%) and no patient died of COVID-19 complications. Nine were male (3.4%), and the mean age of the patients with positive results was 43.2 years (± 9.6). 107 patients (41.1%) were over 50 years of age and their mean T-CD4+ cell count was 768. Eleven patients (4.2%) had a detectable HIV RNA viral load and 127 (48.8%) had comorbidities. These variables were not associated with an increased risk for infection. CONCLUSION: The frequency of SARS-COV2 infection among HIV-infected is similar to the general population, and the clinical course is associated with the presence of comorbidities and not due to the HIV infection. However, new studies should be done to assess if this vulnerable population could answer the vaccine anti-SARS-Cov2.
Asunto(s)
COVID-19 , Infecciones por VIH , VIH-1 , Humanos , Masculino , Persona de Mediana Edad , Anciano , Adulto , Femenino , COVID-19/complicaciones , COVID-19/epidemiología , SARS-CoV-2 , Infecciones por VIH/complicaciones , Infecciones por VIH/tratamiento farmacológico , Infecciones por VIH/epidemiología , Brasil/epidemiología , Progresión de la EnfermedadRESUMEN
ABSTRACT Interferon-gamma (IFN-γ) plays a crucial role in viral infections by preventing viral replication and in the promotion of innate and adaptive immune responses. However, IFN-gamma can exert distinct effects in different persistent viral infections. The long-term overproduction of IFN-γ in retroviral infections, such as the human immunodeficiency virus (HIV), human T-lymphotropic virus type 1 (HTLV-1), and human endogenous retroviruses (HERVs), resulting in inflammation, may cause neuronal damage. This review is provocative about the role of IFN-γ during persistent retroviral infections and its relationship with the causation of some neurological disorders that are important for public health.
RESUMEN
OBJECTIVE: To investigate the frequency and perform a qualitative analysis of spin bias in publications of controlled trials assessing the therapeutic use of cannabis derivatives and their synthetic analogues. STUDY DESIGN AND SETTING: Meta-epidemiologic study carried out at the Universidade Federal de São Paulo, Brazil. RESULTS: A total of 65 publications with at least one efficacy primary outcome were considered. The results analysis for the primary outcome indicated statistically significant effects in 44.6% (29/65) of the publications, and 70.7% (45/65) of the conclusions were considered favorable to the intervention. Among the 36 publications that found statistically nonsignificant results for the primary outcome, 44.4% (16/36) presented conclusions favorable to or recommending the intervention, which represents spin bias according to the definition adopted in this study. Qualitative analysis of the 16 studies with spin bias showed selective outcomes reporting (elevating secondary outcomes that had positive results or reporting only subgroup results), deviations from the planned statistical analysis, and failure to consider or report uncertainty in the estimates of treatment effects. CONCLUSION: The frequency of spin bias among publications of controlled trials with statistically nonsignificant results assessing the therapeutic use of cannabis derivatives and their synthetic analogues reached 44.4%. When not observed by readers, such deviation can lead to misconduct in clinical practice through the adoption of interventions that are not effective or whose effectiveness is uncertain.
Asunto(s)
Sesgo , Cannabinoides/uso terapéutico , Ensayos Clínicos como Asunto/normas , Ensayos Clínicos como Asunto/estadística & datos numéricos , Humanos , Publicaciones Periódicas como Asunto/estadística & datos numéricos , Sesgo de Publicación/estadística & datos numéricos , Resultado del TratamientoRESUMEN
BACKGROUND: Human T-cell lymphotropic virus type 1 (HTLV-1) infection is associated not only with some severe manifestations, such as HTLV-1-associated myelopathy (HAM) and ATLL, but also with other, less severe conditions. Some studies have reported neurologic manifestations that did not meet all the criteria for the diagnosis of HAM in individuals infected with HTLV-1; these conditions may later progress to HAM or constitute an intermediate clinical form, between asymptomatic HTLV-1 carriers and those with full myelopathy. This study evaluated the prognostic value and looked for a possible association of those parameters with the intermediate syndrome (IS) status and HAM status. METHODS: Proviral load (PVL), spontaneous lymphoproliferation, interferon (IFN)-γ spontaneous production was quantified in samples of asymptomatic and HAM patients, as well as patients with IS. RESULTS: The critical age range was 50-60 years for IS outcome and more of 60 years for HAM outcome, with an increased risk of 2.5-fold for IS and 6.8-fold for HAM. IFN-γ was increased in patients with IS compared with asymptomatic carriers (ACs) (p = 0.007) and in patients with HAM compared with ACs (p = 0.03). Lymphoproliferation was increased in patients with HAM vs ACs (p = 0.0001) and patients with IS (p = 0.0001). PVL was similar between groups. CONCLUSION: IFN-γ has high specificity of prediction of subject remain asymptomatic compared with PVL and lymphoproliferation assay tests. IFN-γ has been shown to be a biomarker of progression to intermediate stage and to HAM. The association of other markers with manifestations associated with HTLV-1 infection that does not meet the HAM criteria should be verified.
RESUMEN
Few studies have reported the prognosis of human immunodeficiency virus (HIV)-positive patients followed for a long time in Brazil, particularly those including pre and post-HAART eras. The polymorphisms of interferon (IFN)-λ4 have been postulated as possibly associated with the pathogenesis of HIV infection. The aim of this study was to describe the incidence and mortality from a cohort of HIV-positive patients as well as whether IFN-λ4 gene polymorphisms (SNP rs8099917 and SNP rs12979860) were associated with HIV/acquired immune deficiency syndrome (AIDS) progression. We followed 402 patients for up to 30 years; 347 of them began follow-up asymptomatic, without any AIDS-defining opportunistic disease and/or a lymphocytes T CD4+ count of 350 cells/mm3 or lower. We determined the probability of the asymptomatic subjects to remain AIDS-free, and the risk of death for those entering the study already with an AIDS diagnosis, as well as for subjects developing AIDS during follow-up. We compared the prognosis of patients with two different polymorphisms for the genes encoding for IFN-λ4, variants rs8099917 and rs12979860. The follow-up time of the 347 asymptomatic-at-entry subjects was 3687 person-years. IFN-λ4 rs8099917 polymorphisms were not associated with AIDS progression, but IFN-λ4 rs12979860 wild type genotype (CC) was associated with higher mortality compared to CT and TT, with an increased probability of death from AIDS (P = .01). In conclusion, genetic variations in IFN-λ4 on rs12979860 polymorphisms in HIV-infected patients may drive mortality risk.
Asunto(s)
Síndrome de Inmunodeficiencia Adquirida/genética , Síndrome de Inmunodeficiencia Adquirida/mortalidad , Genotipo , Interleucinas/genética , Polimorfismo de Nucleótido Simple , Síndrome de Inmunodeficiencia Adquirida/tratamiento farmacológico , Síndrome de Inmunodeficiencia Adquirida/inmunología , Adolescente , Adulto , Terapia Antirretroviral Altamente Activa/estadística & datos numéricos , Brasil/epidemiología , Linfocitos T CD4-Positivos , Estudios de Cohortes , Progresión de la Enfermedad , Femenino , Estudios de Seguimiento , Humanos , Incidencia , Interleucinas/clasificación , Interleucinas/inmunología , Masculino , Persona de Mediana Edad , ARN Viral , Carga Viral , Adulto JovenRESUMEN
OBJETIVO: Avaliar a tendência de mortalidade por pneumonia em crianças brasileiras até 4 anos de idade no período de 1991 a 2007. MÉTODOS: Foi realizado um estudo retrospectivo baseado em banco de dados do Departamento de Informática do Sistema Único de Saúde (DATASUS), do qual foram extraídos o número de óbitos por pneumonia e a população residente de até 4 anos de idade nas cinco regiões brasileiras e no país como um todo. O coeficiente de mortalidade foi calculado pelo número de óbitos por pneumonia dividido pela população, multiplicando por 1.000 na faixa etária menor de 1 ano e por 10.000 na faixa etária de 1 a 4 anos. Utilizou-se o teste de regressão linear para avaliar a tendência temporal de mortalidade. RESULTADOS: Observou-se um decréscimo significativo de mortalidade por pneumonia no período estudado em ambas as faixas etárias e em todas as regiões do país. No Brasil como um todo, a redução média anual dos coeficientes de mortalidade na população menor de 1 ano e naquela entre 1 e 4 anos foi de 0,12 e 0,07, respectivamente. As Regiões Sul e Sudeste apresentaram as maiores reduções (-0,14 e -0,18 para < 1 ano; -0,07 e -0,09 para 1 a 4 anos). As menores reduções foram nas Regiões Norte e Nordeste (-0,04 e -0,07) nas crianças menores de 1 ano, e nas Regiões Norte e Centro-Oeste (-0,03 e -0,04) na faixa etária entre 1 e 4 anos. CONCLUSÕES: Houve uma redução significativa na mortalidade por pneumonia em crianças até 4 anos de idade em todo o país no período de 1991 a 2007, porém, uma discrepância entre as diferentes regiões permanece em evidência.
OBJECTIVE: To evaluate the trend of pneumonia mortality in Brazilian children aged 4 years and younger from 1991 to 2007. METHODS: We conducted a retrospective study based on the database of the IT Department of the Brazilian Unified Health System (DATASUS), from which we obtained the number of deaths from pneumonia and the population aged 4 years and younger living in the five Brazilian regions and in the whole country. Mortality rate was calculated according to the number of deaths from pneumonia divided by the population, multiplied by 1,000 for the age group under 1 year old and by 10,000 in the age group from 1 to 4 years. The linear regression test was used to evaluate the time trend of mortality. RESULTS: There was a significant decrease in pneumonia mortality rates during the study period in both age groups and all regions of the country. In Brazil, the mean annual reduction in mortality rates in the population under 1 year old and between 1 and 4 years was 0.12 and 0.07, respectively. The South and Southeast regions showed the greatest reductions (-0.14 and -0.18 for < 1 year and -0.07 and -0.09 for 1 to 4 years). The smallest decreases were in the North and Northeast regions (-0.04 and -0.07) in children younger than 1 year, and in the North and Central West (-0.03 and -0.04) in the age group between 1 and 4 years. CONCLUSIONS: There was a significant reduction in pneumonia mortality in children aged 4 years and younger across the country from 1991 to 2007; however, a discrepancy between the different regions remains evident.
Asunto(s)
Preescolar , Humanos , Lactante , Neumonía/mortalidad , Distribución por Edad , Brasil/epidemiología , Modelos Lineales , Estudios Retrospectivos , Factores de TiempoRESUMEN
OBJECTIVE: To evaluate the trend of pneumonia mortality in Brazilian children aged 4 years and younger from 1991 to 2007. METHODS: We conducted a retrospective study based on the database of the IT Department of the Brazilian Unified Health System (DATASUS), from which we obtained the number of deaths from pneumonia and the population aged 4 years and younger living in the five Brazilian regions and in the whole country. Mortality rate was calculated according to the number of deaths from pneumonia divided by the population, multiplied by 1,000 for the age group under 1 year old and by 10,000 in the age group from 1 to 4 years. The linear regression test was used to evaluate the time trend of mortality. RESULTS: There was a significant decrease in pneumonia mortality rates during the study period in both age groups and all regions of the country. In Brazil, the mean annual reduction in mortality rates in the population under 1 year old and between 1 and 4 years was 0.12 and 0.07, respectively. The South and Southeast regions showed the greatest reductions (-0.14 and -0.18 for < 1 year and -0.07 and -0.09 for 1 to 4 years). The smallest decreases were in the North and Northeast regions (-0.04 and -0.07) in children younger than 1 year, and in the North and Central West (-0.03 and -0.04) in the age group between 1 and 4 years. CONCLUSIONS: There was a significant reduction in pneumonia mortality in children aged 4 years and younger across the country from 1991 to 2007; however, a discrepancy between the different regions remains evident.